ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
… ProQR annonce la publication dans Nature Medicine des données … CAMBRIDGE, Massachusetts, 18 déc. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société qui … commencer au cours du premier semestre 2019. À propos de ProQRProQR Therapeutics s’efforce de changer les vies grâce …
… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the …
… ProQR Strengthens its Scientific Advisory Board with the … SAB. Science is at the core of everything we do at ProQR, and with this group as our key advisors we can be more … of success that will be invaluable as we advance our R&D programs and our broader RNA technologies, including the …
… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … securities laws of any such state or jurisdiction. About ProQRProQR Therapeutics is dedicated to changing lives …